PCRX
NASDAQPacira BioSciences Inc.
Price$25.52+2.04 (+8.67%)
2026-05-212026-08-25
News · 26 weeks81+200%
2026-03-012026-08-23
Mix4190d
- Insider14(34%)
- Other13(32%)
- SEC Filings9(22%)
- Leadership2(5%)
- Earnings2(5%)
- Analyst1(2%)
Latest news
25 items- INSIDERChief Medical Officer Slonin Jonathan sold $70,619 worth of shares (3,040 units at $23.23) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 216,384 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- ANALYSTTruist resumed coverage on Pacira BioSciences with a new price targetTruist resumed coverage of Pacira BioSciences with a rating of Buy and set a new price target of $30.00
- SECSEC Form SCHEDULE 13G filed by Pacira BioSciences Inc.SCHEDULE 13G - Pacira BioSciences, Inc. (0001396814) (Subject)
- PRPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on August 4, 2026 to five new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the "Inducement Plan") as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the "Committee") without stockholder approval. Two employees received stock options to purchase
- PRPacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis — — Exploratory clinical outcome measures showed improvements out to two years in pain, stiffness, and function across all doses and groups — — Phase 2 ASCEND trial of PCRX-201 in knee osteoarthritis advancing with first topline read out on track for year-end 2026 — BRISBANE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the publication of positive two-year r
- SECSEC Form S-8 filed by Pacira BioSciences Inc.S-8 - Pacira BioSciences, Inc. (0001396814) (Filer)
- SECSEC Form 10-Q filed by Pacira BioSciences Inc.10-Q - Pacira BioSciences, Inc. (0001396814) (Filer)
- SECPacira BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRPacira BioSciences Reports Second Quarter 2026 Financial Results-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue of $192.4 million, representing 6 percent year-over-year growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the second quarter of 2026. "The first half of 2026 was marked by solid revenue growth and strong execution of our 5x30 strategy acros
- PRPacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product from new manufacturing process —— Topline data from Part A of Phase 2 ASCEND study remains on track for end of year — BRISBANE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has successfully transitioned PCRX-201 (enekinragene inzadenovec), its investigational locally administered gene therapy for osteoarthritis of the knee, to a U.S.-based scalable commercial manufacturing process intended to support future reg
- PRPacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026BRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter 2026 financial results after the close of the U.S. markets on Tuesday August 4, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the
- PRPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2026 to ten new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the "Inducement Plan") as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the "Committee") without stockholder approval. Four employees received stock options to purchase a
- PRPacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that UnitedHealthcare now provides separate reimbursement for EXPAREL® (bupivacaine liposome injectable suspension) across outpatient settings, including hospital outpatient departments and ambulatory surgery centers. This update enables EXPAREL to be reimbursed outside of the surgical bundle for eligible UnitedHealthcare members, representing an additional step i
- SECPacira BioSciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
- PRPacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments -- -- Two companies will collaborate on advancing the spasticity program -- -- Supports 5x30 strategy and advances Pacira’s transition into an innovative biopharmaceutical company -- BRISBANE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced the divestiture of iovera ®° to Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader. The iover
- INSIDERDirector Hirawat Samit was granted 6,405 shares (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERSenior Vice President, Finance Riker Lauren sold $143,702 worth of shares (6,115 units at $23.50) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 62,284 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERSEC Form 4 filed by Director Wiggans Thomas G4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Christie Christopher was granted 6,405 shares, increasing direct ownership by 38% to 23,059 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Young Alethia was granted 6,405 shares, increasing direct ownership by 56% to 17,798 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Yang Michael J. was granted 6,405 shares, increasing direct ownership by 48% to 19,798 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Bigal Marcelo was granted 6,405 shares, increasing direct ownership by 56% to 17,798 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Brege Laura was granted 6,405 shares, increasing direct ownership by 27% to 30,120 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERDirector Froimson Mark was granted 6,405 shares, increasing direct ownership by 32% to 26,541 units (SEC Form 4)4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wiggans Thomas G3 - Pacira BioSciences, Inc. (0001396814) (Issuer)
PCRX FAQ
7 questionsWhat does Pacira BioSciences Inc. do?
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a bupivacaine liposome injectable suspension, administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver...Where does PCRX stock trade?
Pacira BioSciences Inc. (PCRX) is listed on NASDAQ.What sector and industry is PCRX in?
Pacira BioSciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Pacira BioSciences Inc. go public?
Pacira BioSciences Inc. (PCRX) completed its IPO in 2011.What are analysts saying about PCRX?
Pacira BioSciences Inc. has had 8 recent analyst actions on file. The most recent action was from Truist: Buy with a $3000.00 price target on 2026-08-17. Recent price targets range from $800.00 to $3000.00.What companies are similar to PCRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PCRX side-by-side with any of them on Quantisnow.How can I track PCRX on Quantisnow?
Quantisnow aggregates Pacira BioSciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PCRX to receive live email and push alerts on every new disclosure.